Observational studyEye (London, England)2025
Clinical outcomes of ocular syphilis within the Great Plains region: potential syndemic impact of methamphetamine use.
Observational study in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND/
objectivesTo characterise the clinical spectrum of ocular syphilis and its visual acuity impact in patients with and without methamphetamine use. SUBJECTS/
methodsThis retrospective observational case series of patients with ocular syphilis was conducted at a tertiary referral centre within the Midwest United States. Patients diagnosed with ocular syphilis between 2021 and 2023 at the University of Nebraska Medical Center were included in the study. Patients were stratified into methamphetamine use and non-methamphetamine use groups. Paired, non-parametric comparisons of visual characteristics and visual outcomes at baseline, month-3, and month-6 were performed between the two groups.
resultsA total of 34 eyes of 21 patients were included in the analysis. The median age was 44 years (39- 53), and fifteen patients (71%) were male. The median baseline visual acuity (VA) was 6/60 (6/45.7-LP) in the methamphetamine group (11 eyes, n = 7), which was significantly worse than the non-methamphetamine group (23 eyes, n = 14) with the median VA of 6/18 (6/7.5-6/45.7), p = 0.0136. While the non-methamphetamine group exhibited a significant VA improvement from baseline to month-3 follow-up (6/18-6/7.5, p = 0.001) and from baseline to month-6 follow-up (6/21-6/6, p = 0.002), this was not seen in the methamphetamine group (6/120-6/24, p = 0.225). Duration from symptom onset to presentation was shorter within the methamphetamine group compared to the non-methamphetamine group (7 days vs 36 days, p = 0.024).
conclusionsMethamphetamine use was associated with worse visual acuity at presentation and follow-up despite patients presenting sooner for evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.